Pfizer Announces Phase 3 MagnetisMM-5 Results for Elrexfio in Combination Regimen

Pfizer today announced results from the Phase 3 MagnetisMM-5 trial evaluating elranatamab (Elrexfio) plus daratumumab and lenalidomide in patients with relapsed or refractory multiple myeloma. The trial met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival compared to daratumumab plus lenalidomide and dexamethasone. These results support the potential of elranatamab in combination regimens for multiple myeloma. Pfizer plans to submit regulatory applications for this combination based on these results.